Physician profile
Sandra Okere
NPI 1104323344
$4,322.23
in general payments reported to CMS, 2019-2025
23 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.59 · 2022: $291 · 2023: $885 · 2024: $1,042 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,939 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,938.74 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,250.67 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Genzyme Corporation | $919.90 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $787.16 | 2023-2025 | Dupixent |
| Optinose US, INC. | $261.93 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $242.26 | 2025 | Neffy |
| Kaleo, INC. | $120.76 | 2023-2024 | Auvi-Q |
| Organon LLC | $99.46 | 2025 | Vtama |
| Alk-Abello, INC | $94.65 | 2022-2023 | Odactra, Grastek |
| Genentech USA, INC. | $87.86 | 2023-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $76.44 | 2025 | Takhzyro |
| Hikma Pharmaceuticals USA | $61.09 | 2024-2025 | Ryaltris |
| Glaxosmithkline, LLC. | $44.71 | 2021-2024 | Nucala, Trelegy Ellipta |
| Amgen INC. | $44.65 | 2022 | |
| Genentech, INC. | $35.43 | 2023 | Xolair |
| Inspire Medical Systems, INC. | $26.07 | 2023 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $25.65 | 2022 | |
| Incyte Corporation | $24.52 | 2025 | Opzelura |
| Blueprint Medicines Corporation | $22.91 | 2024 | |
| Novartis Pharmaceuticals Corporation | $22.84 | 2025 | |
| Novo Nordisk INC | $21.50 | 2022 | |
| Covis Pharma Gmbh | $19.82 | 2022 | |
| Phadia US INC. | $17.31 | 2025 | Immunocap |
| Innovation Technologies INC | $14.64 | 2025 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Okere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.